Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VaxigripTetra
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VaxigripTetra (also known as the Shenzhen Quadrivalent Influenza Vaccine) is a quadrivalent inactivated split-virion influenza vaccine developed and manufactured by Sanofi Pasteur at their facility in Shenzhen, China. It is designed to provide active immunization against four influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata), following annual World Health Organization (WHO) recommendations. As a split-virion vaccine, the viral particles are chemically disrupted and inactivated to eliminate pathogenicity while retaining the immunogenicity of the hemagglutinin (HA) surface proteins. The vaccine is primarily indicated for the prevention of influenza disease in individuals aged 6 months and older and is specifically tailored for the Chinese market.
- Brand names
- VaxigripTetraVaxigrip
- Other names
- Shenzhen Quadrivalent Influenza VaccineShenzhen Quadrivalent Inactivated Influenza VaccineSP Shz QIV
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on VaxigripTetra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VaxigripTetra.